A1C Almanac

Main Page

Sauerkraut-Derived Vitamin K2 as a Functional Dietary Lever for Bone, Vascular, and Metabolic Health

Posted

by

dr Karunia Valeriani Japar

Table of Contents
Category:

Introduction

Vitamin K is a fat-soluble micronutrient that exists as phylloquinone (vitamin K1) and a family of menaquinones (vitamin K2), which differ in isoprenoid side-chain length and tissue distribution. Whereas K1 is predominantly obtained from green leafy vegetables and is primarily utilized in the liver for the γ-carboxylation of coagulation factors, K2 is more efficiently retained in the circulation, exhibits longer half-lives, and preferentially accumulates in extra-hepatic tissues such as bone and vasculature. In these sites, K2 serves as an essential cofactor for γ-glutamyl carboxylase, enabling the activation of vitamin K–dependent proteins including osteocalcin and matrix Gla protein (MGP), which coordinate calcium homeostasis by promoting mineral deposition in bone while preventing ectopic calcification in soft tissues. Undercarboxylation of these proteins has been linked to impaired bone quality and increased vascular calcification, providing a mechanistic rationale for the observed associations between higher K2 intake, reduced fracture risk, and improved cardiovascular outcomes in epidemiologic and interventional studies. Consequently, vitamin K2 has emerged as a promising nutritional target in strategies aimed at preventing osteoporosis and cardiovascular disease, two leading contributors to disability and mortality in aging populations.

In parallel with this mechanistic insight, there has been growing recognition of bacterially synthesized menaquinones in fermented foods as accessible dietary sources of K2. Fermented soy products such as natto, various cheeses, and other microbially transformed foods harbour bacteria that synthesize distinct menaquinone profiles, contributing substantially to K2 intake in populations with traditional consumption of these foods. Sauerkraut, a lactic acid–fermented cabbage, has recently attracted attention as a plant-based source of vitamin K2 that may be particularly relevant for individuals with low consumption of animal products or who prefer food-first approaches to supplementation. Produced by fermenting finely shredded cabbage with salt under predominantly lactic acid bacteria (LAB)–driven conditions, sauerkraut is rich in organic acids, live microbes (in unpasteurized products), and various micronutrients, and has been linked to favourable effects on gut microbiota and intestinal barrier function. Emerging compositional analyses indicate that during fermentation, selected microbial communities synthesize menaquinones, with reported vitamin K2 contents in sauerkraut ranging from approximately 2.75 to 6 μg per half to one cup serving, although values vary widely across products and batches.

For clinicians and AI-enabled wellness platforms focused on longevity and the prevention of metabolic and vascular disease, sauerkraut therefore represents a culturally familiar, low-cost, plant-forward vehicle to augment K2 intake while simultaneously modulating the gut ecosystem. Integrating sauerkraut into dietary protocols could, in principle, support more optimal calcium handling, bone quality, and vascular health, while contributing to microbial diversity and reduced low-grade inflammation pathways central to cardiometabolic resilience. However, the vitamin K2 content of sauerkraut is highly variable and depends on cabbage cultivar, indigenous and starter microbial strains, salt concentration, fermentation temperature and duration, and post-processing steps such as pasteurization, all of which complicate efforts to define standardized “doses” or to extrapolate supplement trial data to food-based interventions. This review will summarize the mechanistic underpinnings of vitamin K2 in bone–vascular biology, examine the evidence for bacterially derived K2 in sauerkraut and related fermented foods, and discuss practical strategies for incorporating sauerkraut into preventive and longevity-oriented care, with particular attention to opportunities and constraints within AI-driven, personalized nutrition ecosystems.

Vitamin K2 Biology and Mechanisms

Vitamin K2 refers to a family of menaquinones (MK-n), typically ranging from MK-4 to MK-13, characterized by differing lengths of isoprenoid side chains that influence their absorption, tissue distribution, and biological activity. These compounds are produced endogenously by gut microbiota and exogenously by bacteria used in food fermentation, leading to their presence in fermented foods such as natto, cheese, and sauerkraut. Longer-chain menaquinones, particularly MK-7, exhibit higher bioavailability and markedly longer plasma half-lives than vitamin K1 and shorter-chain K2 forms, resulting in more stable circulating levels and enhanced delivery to extra-hepatic tissues. Pharmacokinetic studies report an elimination half-life of approximately 3 days for MK-7, compared with only a few hours for vitamin K1, underscoring MK-7’s capacity to sustain activation of vitamin K–dependent proteins outside the liver. These pharmacologic features provide a mechanistic basis for considering MK-7 and related menaquinones as particularly relevant to bone and vascular health [1,2,3,4,5,6,7,8,9].

Figure 1. Mechanisms of action of VitK2 in “bone and vascular cross-talk” [8]

Within the vitamin K cycle, K2 functions as an essential cofactor for γ-glutamyl carboxylase (GGCX), which catalyzes the conversion of specific glutamate (Glu) residues to γ-carboxyglutamate (Gla) on vitamin K–dependent proteins. Among the extra-hepatic vitamin K–dependent proteins, osteocalcin (OC) in bone and matrix Gla protein (MGP) in vascular tissue are particularly critical for calcium handling and “bone–vascular crosstalk.” Carboxylated osteocalcin (cOC) has a high affinity for calcium and hydroxyapatite, facilitating the incorporation of calcium into the bone matrix and enhancing bone mineralization and mechanical strength. In contrast, carboxylated MGP (cMGP) acts as a potent inhibitor of vascular calcification by binding calcium-phosphate crystals, preventing their deposition in the arterial wall, and by suppressing osteogenic trans-differentiation of vascular smooth muscle cells via inhibition of bone morphogenetic protein-2 (BMP-2) signalling. Insufficient K2 intake leads to higher circulating levels of undercarboxylated osteocalcin (ucOC) and dephosphorylated–undercarboxylated MGP (dp-ucMGP), biomarkers associated with impaired bone quality and increased vascular calcification [5,8,9,10,11].

Beyond its canonical role in γ-carboxylation, vitamin K2 appears to modulate additional pathways linked to mitochondrial function, oxidative stress, and inflammation. Experimental studies suggest that K2 can influence mitochondrial electron transport, reduce reactive oxygen species, and affect signalling cascades such as NF-κB and Wnt/β-catenin, thereby impacting osteoblast and osteoclast activity as well as vascular smooth muscle cell survival. Emerging data in metabolic disease models indicate that MK-7 may improve insulin sensitivity and glucose homeostasis, potentially through effects on mitochondrial bioenergetics and inflammatory tone, but human data remain limited and heterogeneous. These pleiotropic actions support the concept of K2 as more than a coagulation cofactor, positioning it as a regulator of cellular energy and stress responses in bone and vascular tissues [8,9,11,12,13].

A growing body of evidence highlights synergistic interactions between vitamin K2 and vitamin D in calcium metabolism and cardio-metabolic health. Vitamin D enhances intestinal calcium absorption and contributes to osteoblast differentiation, while K2 ensures that the absorbed calcium is appropriately utilized through the activation of OC and MGP, directing calcium toward bone and away from arteries. Clinical trials combining K2 (often MK-7) with vitamin D have demonstrated reductions in dp-ucMGP levels and attenuation of coronary artery calcification progression in selected high-risk populations, suggesting that co-supplementation can beneficially influence the bone–vasculature axis. This nutrient synergy offers a plausible mechanistic bridge between micronutrient status and long-term cardio-metabolic risk, especially in aging individuals or those with chronic diseases characterized by concurrent bone loss and vascular calcification [8,9,13,14].

Observational cohorts and interventional trials provide supportive, though not yet definitive, evidence linking higher K2 intake or status to improved clinical outcomes. Prospective studies have associated greater dietary K2 intake with reduced risk of hip fractures, improved bone mineral density, and lower incidence of coronary heart disease and severe arterial calcification. Meta-analyses of randomized controlled trials, primarily using pharmacologic doses of MK-4 or supplemental MK-7, report beneficial effects on bone mineral density, fracture risk, and biomarkers of vitamin K status, although results vary by population, dose, and K2 form. Heterogeneity in study design and the predominance of supplement-based interventions limit direct extrapolation to food-based sources such as sauerkraut, where the absolute K2 dose is lower and embedded within complex food matrices. Nonetheless, the convergence of biochemical, epidemiologic, and clinical data supports the view of vitamin K2 as a strategic micronutrient in managing the bone–vascular axis and attenuating age-related calcification processes. In this context, improving access to and habitual intake of K2-rich foods, including fermented products that provide bacterially derived menaquinones, can be considered a rational component of preventive and longevity-oriented care [2,3,6,8,9,13,15,16,17].

Bacterially Produced Vitamin K2 in Fermented Foods

Multiple microorganisms associated with fermented foods and the human gut synthesize menaquinones (vitamin K2) as part of their anaerobic respiratory and energy metabolism, leading to vitamin K2 accumulation in a variety of food matrices. Species such as Bacillus subtilis, Propionibacterium freudenreichii, and selected lactic acid bacteria (LAB) are particularly important producers, and their activity during fermentation can markedly increase the K2 content of plant- and dairy-based products. In this context, fermented soybeans (natto and related products) are among the richest known dietary sources of MK-7, with Bacillus subtilis natto responsible for very high menaquinone production that translates into tens to hundreds of micrograms of K2 per serving. Cheese and fermented milk products also contribute substantially to dietary K2, with menaquinone profiles that reflect the composition and metabolic capacity of starter and adjunct bacterial cultures used in their manufacture [3,7,18,19,20,21].

Recent analytical work on fermented dairy products illustrates how fermentation conditions and starter culture selection shape the final MK-7 content. In one evaluation, MK-7 concentrations increased during fermentation and ripening, reaching up to approximately 4.8 μg per 100 g in kefir produced with natural kefir grains, whereas products made with selected single-strain starters contained lower amounts. Similarly, systematic surveys of cheese have shown that both hard and soft cheeses contain mixtures of K2 analogues (e.g., MK-4 through MK-10), with total K2 concentrations strongly influenced by fat content, ripening duration, and microbial consortia. Dutch-style and certain French cheeses can reach total menaquinone contents in the range of 400–800 ng/g, with longer ripening generally associated with higher levels due to prolonged bacterial activity and accumulation of long-chain menaquinones. By contrast, some Mediterranean cheeses and fresh curd cheeses contain much lower K2 levels, highlighting considerable inter-product variability [19,20,22,23].

Regulatory and safety assessments of MK-7 as a food ingredient acknowledge that mixtures of menaquinones naturally present in foods such as cheese and sauerkraut make a non-trivial contribution to baseline K2 intake, even among individuals who do not use supplements. Authorities such as Food Standards Australia New Zealand (FSANZ) have reviewed toxicological and pharmacokinetic data and concluded that MK-7 is a safe and bioavailable form of vitamin K for use in specific food categories, implicitly recognizing that habitual exposure to bacterially produced K2 from fermented foods is part of normal dietary patterns. At the same time, compositional studies demonstrate that K2 content in fermented foods can vary by an order of magnitude or more between brands, batches, and production systems, due to differences in raw materials, microbial strains, fermentation time and temperature, and post-processing (e.g., pasteurization). This variability complicates efforts to precisely quantify K2 intake from natural sources and to translate supplement-based dose–response data into food-based clinical protocols [3,7,15,19,24,25].

From a public health and digital health perspective, this heterogeneity represents both an opportunity and a challenge. On the one hand, fermented foods are widely accessible, culturally embedded vehicles that can incrementally raise K2 intake alongside other beneficial components such as probiotics, organic acids, and B vitamins. On the other hand, the lack of standardized labelling and limited product-level analytics make it difficult to prescribe fermented foods for drug-like dosing of K2, especially in high-risk patients or interventional trial settings. For health-tech systems that prioritize behavioural nudging and probabilistic risk reduction over precise nutrient pharmacotherapy, even modest but consistent increases in K2 exposure via regular consumption of natto, selected cheeses, kefir, sauerkraut, and other ferments may still yield meaningful long-term benefits when integrated with optimized dietary patterns, physical activity, and cardiometabolic risk management. In this framing, bacterially produced vitamin K2 in fermented foods can be viewed as a scalable, food-based lever to support bone–vascular health within comprehensive, personalized prevention strategies [3,7,15,18,19,26].

Sauerkraut as a Source of Vitamin K2

Sauerkraut is produced by spontaneous or starter-guided lactic acid fermentation of finely shredded cabbage mixed with salt, a process that allows lactic acid bacteria (LAB) and associated microbiota to proliferate, acidify the environment, and structurally and biochemically transform the vegetable substrate. During fermentation, these microorganisms convert cabbage carbohydrates into lactic acid and a range of flavor compounds, while also synthesizing micronutrients, including selected menaquinones that contribute to the vitamin K2 content of the final product. Compositional data from food databases and consumer-oriented technical summaries indicate that a typical half-cup serving of sauerkraut (approximately 70–75 g) provides around 2.75 μg of vitamin K2, with reported ranges up to roughly 6 μg per half-cup and occasionally higher values in larger or more intensely fermented servings. Older analytical reports and review articles have suggested K2 contents on the order of 4.8–5.5 μg per 100 g, although these estimates likely reflect specific products and highlight the need for more systematic profiling. Regulatory dossiers and technical documents further note that sauerkraut contains a mixture of K2 analogues, yet detailed speciation (e.g., relative proportions of MK-4, MK-6, MK-7, MK-8, MK-9) and harmonized reference values remain sparse in public food composition databases [2,24,25,27].

Figure 2. Dietary Sources of Vitamin K [27]

Experimental investigations of fermented cabbage products have detected multiple menaquinone forms, particularly menaquinone-4 (MK-4) and menaquinone-7 (MK-7), with the dominant species varying according to fermentation technique and microbial consortia. Key determinants of vitamin K2 formation include cabbage cultivar, the initial epiphytic microbial community, salt concentration, temperature, oxygen availability, and fermentation duration, all of which shape bacterial growth curves and metabolic outputs. Longer fermentation times and specific LAB strains appear to favor greater menaquinone accumulation, although prolonged storage or exposure to light and heat may degrade both K vitamins and other labile micronutrients. Post-fermentation processing is equally critical: pasteurization and high-heat treatments can inactivate live bacteria and may attenuate vitamin synthesis or stability, whereas raw, unpasteurized sauerkraut with “live and active cultures” retains both microbial viability and any K2 already produced. Consequently, raw products are often positioned as delivering combined probiotic and micronutrient benefits, although precise quantification of K2 content at the point of consumption is rarely available [2,24,27,28,29].

From a dietary perspective, sauerkraut occupies a distinctive niche as a rare plant-based source of vitamin K2, complementing K1-rich leafy greens and helping to bridge the gap between minimal and moderate K2 intake in individuals who consume little or no animal organs, aged cheeses, or natto. In addition to K2, sauerkraut provides vitamin K1, vitamin C, fiber, and diverse LAB strains, which may collectively support bone health, vascular function, and gut microbiota diversity, although direct interventional data specific to sauerkraut remain limited. For plant-forward or flexitarian dietary patterns, regular inclusion of raw sauerkraut, at serving sizes on the order of 50–100 g several times per week can be framed as a pragmatic, food-first strategy to incrementally raise K2 exposure while delivering broader fermentation-related benefits. Given the variability in reported K2 concentrations across brands and batches, however, sauerkraut is best viewed not as a precisely dosed K2 delivery system but as one component of a diversified K2 intake pattern that also includes other fermented and animal-derived sources where acceptable [2,24,27,29,30,31].

Metabolic, Bone, and Cardiovascular Health Implications

Vitamin K2’s principal physiological relevance lies in its role in systemic calcium handling, with downstream effects on bone density, fracture risk, and vascular calcification. As a cofactor for γ-glutamyl carboxylase, K2 enables the carboxylation of osteocalcin, which enhances the binding of calcium to hydroxyapatite in bone, thereby improving mineralization and potentially reducing osteoporotic fracture risk, particularly in aging and postmenopausal populations. Randomized trials and meta-analyses of K2 (mainly MK-4 and MK-7) report improvements in bone turnover markers, reductions in undercarboxylated osteocalcin, and signals for reduced fracture incidence, although results vary with dose, duration, and baseline risk. In parallel, K2-dependent activation of matrix Gla protein (MGP) in the arterial wall acts as a potent inhibitor of vascular calcification by binding calcium crystals and preventing their incorporation into the vascular media, contributing to lower arterial stiffness and attenuated atherosclerotic burden. Observational and interventional data link low vitamin K status, as assessed by inactive dp-ucMGP, with increased arterial stiffness, vascular and valvular calcification, and higher cardiovascular mortality, whereas higher K2 intake or supplementation tends to improve surrogate markers of vascular health [8,9,10,32,33,34,35,36,37].

Clinical and mechanistic work supports synergistic interactions between vitamin K2 and vitamin D within this bone–vascular axis. Vitamin D enhances intestinal calcium absorption and contributes to osteoblast differentiation, while K2 ensures appropriate utilization of this calcium by activating osteocalcin and MGP, thereby directing calcium toward bone and away from arteries and soft tissues. Trials and narrative reviews suggest that combined K2–vitamin D supplementation can improve bone turnover profiles and reduce indices of vascular vitamin K deficiency (e.g., dp-ucMGP), and may slow the progression of arterial stiffness and calcification in selected populations. This nutrient synergy provides a biologically plausible mechanism by which optimizing K2 status could reduce long-term cardio-metabolic risk in aging or high-risk individuals [8,9,14,34,38].

Beyond the bone–vascular interface, vitamin K2 may exert broader metabolic effects through modulation of mitochondrial function, ATP production, and inflammatory signaling, although human data remain preliminary. Experimental work suggests that MK-7 can influence mitochondrial electron transport and reduce oxidative stress, while animal and early human studies hint at improvements in insulin sensitivity and glycemic control, but large, definitive trials in type 2 diabetes and obesity are still lacking. Fermented foods such as sauerkraut introduce an additional layer of influence on metabolic health via effects on the gut microbiota, intestinal barrier integrity, and low-grade inflammation, pathways closely linked to insulin resistance, obesity, and cardiometabolic risk. Controlled interventions with sauerkraut have shown that both pasteurized and unpasteurized products can alter gut microbial composition, and pasteurized sauerkraut in particular has been associated with increases in circulating short-chain fatty acids, metabolites implicated in improved barrier function and metabolic regulation [8,12,38,39,40].

As a low-calorie, fiber-containing, probiotic (when raw) food with modest but measurable K2 content, sauerkraut can reasonably be framed as a functional component of dietary patterns aimed at metabolic flexibility, weight control, and cardiometabolic risk reduction, especially when combined with other K2-rich foods and lifestyle interventions such as resistance training and optimization of vitamin D status. Although the absolute K2 dose provided by typical sauerkraut servings (on the order of a few micrograms per half-cup) is considerably lower than that used in pharmacologic MK-4 or MK-7 supplementation trials, regular inclusion in habitual eating may still incrementally shift long-term vitamin K2 status in a favourable direction, particularly at a population level. In this context, sauerkraut and other fermented foods can be viewed as scalable, food-based levers that complement targeted supplementation and broader lifestyle strategies within comprehensive, preventive frameworks for bone, vascular, and metabolic health [8,16,29,30,31,34,40,].

Practical Dietary Integration and Considerations

From a practical perspective, sauerkraut is easy to incorporate into routine meals because it can be used as a ready-to-eat side or condiment added to salads, grain bowls, sandwiches, and traditional dishes with minimal preparation. To maximize both vitamin K2 and probiotic exposure, raw, unpasteurized sauerkraut labelled as containing “live” or “active cultures” and free from vinegar and preservative additives is preferable, since heat processing and pasteurization can markedly reduce microbial viability and may diminish fermentation-derived nutrient content. Typical suggested portions of approximately 50–100 g several times per week provide microgram-level K2 while also delivering fiber, organic acids, and microbiota-modulating lactic acid bacteria, although specific K2 dosing thresholds for defined clinical outcomes have not yet been established. For individuals who consume limited animal-based K2 sources, such as those avoiding organ meats and aged cheeses, regular inclusion of sauerkraut can be particularly relevant, complementing other K2-rich options such as natto, certain cheeses, and egg yolks [30,31,41].

Several limitations and cautions should inform clinical and public health recommendations. Many commercial sauerkraut products are relatively high in sodium, with one cup often supplying a substantial fraction of daily recommended intake, which may be problematic in people with hypertension, heart failure, kidney disease, or salt-sensitive blood pressure; in such cases, smaller portions, low-sodium products, or rinsing the sauerkraut (which can reduce sodium by an estimated 30–40%) may be advisable. Individuals treated with vitamin K antagonists such as warfarin should be counselled to maintain a consistent intake of vitamin K–containing foods, since significant fluctuations in either K1 or K2 intake can affect anticoagulation stability; shifting to a more K2-rich pattern that includes sauerkraut should ideally be coordinated with clinicians and INR monitoring. Because K2 content varies substantially between sauerkraut brands and batches, health-tech platforms and clinicians should model its contribution as a probabilistic range rather than a fixed dose, integrating food-frequency data with periodic biomarker assessments (e.g., dp-ucMGP, undercarboxylated osteocalcin) where feasible. Finally, user education on reading labels (raw vs pasteurized, true fermentation vs vinegar-based products) and on combining sauerkraut with other K2-rich foods such as natto, hard and soft cheeses, and egg yolks can help build a more robust and diversified K2 intake pattern without over-reliance on any single item [2,24,30,31,41,42,43,44].

Future Directions for Research and Digital Health Integration

Although vitamin K2 from fermented foods is biologically plausible as a contributor to bone–vascular and metabolic health, important evidence gaps remain, particularly for sauerkraut. Current food composition work documents menaquinones in cheeses, natto, and selected fermented vegetables, but high-resolution profiling of individual menaquinone species (MK-4, MK-7, and other MK-n) across diverse sauerkraut products is sparse, limiting the ability to ascribe specific systemic effects to particular K2 isoforms or to build accurate food tables for modelling intake. Most interventional data on K2 and clinical endpoints such as fractures, bone mineral density, arterial calcification, and cardiometabolic markers derive from pharmacologic MK-4 or MK-7 supplementation trials rather than from sauerkraut or comparable fermented vegetables, making food-to-outcome extrapolation indirect. Furthermore, while fermented foods clearly modulate gut microbiota and fermentation-derived metabolites, the specific interplay between sauerkraut-derived K2, microbiome shifts, and host metabolic phenotypes remains largely inferential and would benefit from integrated metabolomic and microbiome-based studies using standardized sauerkraut preparations [2,3,8,45,46,47,48,49,50].

These gaps create a rich agenda for future research that bridges nutrition science, microbiology, and digital health. Priority areas include systematic, product-level menaquinone profiling for commercial sauerkraut (and other vegetable ferments), controlled dietary interventions assessing bone, vascular, and metabolic endpoints using realistic intake levels, and mechanistic studies disentangling the contributions of K2 from those of microbial and fiber-mediated effects. Parallel developments in AI-driven precision fermentation and hyper-personalized nutrition indicate that machine learning and high-throughput analytics can be used to optimize microbial consortia for K2 production and to tailor fermented foods to individual metabolic and microbiome profiles. Applying similar tools to sauerkraut could enable targeted enhancement of MK-7 or other menaquinones, while maintaining sensory and cultural acceptability [3,7,18,23,47,51,52].

For AI-driven health-tech platforms, sauerkraut offers a useful case study in operationalizing “nutrient-plus-microbiome” foods within personalized prevention frameworks. Digital systems can incorporate K2-rich food frequency as a variable in risk models for osteoporosis and cardiovascular disease, adjusting recommendations based on dietary patterns, biomarkers (e.g., dp‑ucMGP, undercarboxylated osteocalcin), imaging data (bone density, coronary calcium), medications, and comorbidities. Linking self-reported intake of K2-rich fermented foods with continuous or periodic data such as DXA scans, vascular imaging, or calcification scores could help validate whether food-based K2 materially shifts risk trajectories, and could refine probabilistic estimates of benefit at different intake levels. Finally, user-facing education modules can reframe sauerkraut from a traditional side dish into a functional vehicle for bacterial K2 and microbiota support, embedding it within broader interventions that integrate diet, physical activity, sleep, and stress management, and thereby aligning everyday food choices with long-term metabolic and longevity-oriented goals [3,8,45,46,47,50,53].

Conclusion

Vitamin K2 has emerged as a pivotal micronutrient at the intersection of skeletal integrity, vascular biology, and metabolic regulation, largely through its role in activating extra-hepatic vitamin K–dependent proteins such as osteocalcin and matrix Gla protein. By simultaneously promoting calcium deposition in bone and limiting ectopic mineralization in soft tissues, K2 addresses the “bone–vascular crosstalk” that underlies the coexistence of osteoporosis and vascular calcification in aging populations, and is increasingly regarded as a nutritional lever for health span extension. Accumulating clinical and mechanistic data suggest that adequate K2 status is associated with improved bone mineral density, reduced fracture risk, and slower progression of arterial calcification, although large, well-powered randomized trials are still underway to clarify causality and optimal dosing.

Within this framework, bacterially produced menaquinones in fermented foods represent an underutilized but promising avenue for dietary optimization. Sauerkraut, a lactic acid–fermented cabbage, provides modest yet meaningful amounts of vitamin K2 together with dietary fiber, organic acids, and live microbes (in raw products), aligning it with plant-forward strategies aimed at preventing osteoporosis, vascular calcification, and metabolic dysfunction. Typical compositional analyses indicate that a half-cup of sauerkraut may supply approximately 2.75–6 μg of K2, complementing other K2-rich foods such as natto and certain cheeses and offering a culturally familiar, low-cost option for individuals who favour food-first or predominantly plant-based approaches. Although these amounts are lower than pharmacologic MK-7 doses used in supplementation trials, the integration of sauerkraut into habitual dietary patterns may still exert meaningful cumulative effects when combined with broader dietary and lifestyle interventions.

At the same time, important limitations temper the strength of current recommendations. The K2 content of sauerkraut is highly variable, influenced by cabbage variety, microbial consortia, fermentation conditions, and post-processing, making precise intake estimates and dose–response modelling challenging. Moreover, there is a paucity of intervention studies directly testing sauerkraut itself, rather than isolated menaquinone supplements on clinically relevant endpoints such as fracture incidence, bone mineral density, arterial calcification, or cardiometabolic outcomes. These gaps underscore the need to frame sauerkraut as part of a broader K2- and microbiota-supportive dietary pattern, rather than a stand-alone therapeutic agent, while rigorous trials continue to elucidate its specific contributions.

For clinicians and AI-enabled wellness platforms, incorporating raw, minimally processed sauerkraut into personalized nutrition programs can reasonably be considered a low-risk, potentially high-yield strategy to support long-term health span, especially when aligned with other evidence-based interventions (e.g., adequate vitamin D, resistance training, metabolic risk management). From a research and digital health perspective, future priorities include standardized profiling of menaquinone species and concentrations in commercially available sauerkraut, controlled trials assessing its impact on bone, vascular, and metabolic endpoints, and the integration of K2-rich fermented foods into AI-driven preventive care models that link dietary behaviours with longitudinal biomarker and imaging data. Such work will be essential to move from plausible mechanistic and epidemiologic rationale toward quantitatively grounded, personalized recommendations that leverage sauerkraut and other fermented foods as part of comprehensive strategies for metabolic and longevity-focused care

Reference

  1. EXCERPTED FROM: Vitamin and Mineral Safety 4th Edition (2025) Council for Responsible Nutrition (CRN) https://www.crnusa.org/resources/vitamin-mineral-safety Vitamin K2 -Menaquinone-7 bw body weight CNS Chinese Nutrition Society CRN Council for Responsible Nutrition DRI dietary reference intake EC SCF European Commission Scientific Committee on Food EFSA European Food Safety Authority EVM Expert Group on Vitamins and Minerals HOI highest observed intake level [Internet]. Available from: https://crnusa.org/sites/default/files/pdfs/09.2-CRNVMS4-VITAMINK2_MK7_FINAL-EHedits.pdf
  2. Walther B, Karl JP, Booth SL, Boyaval P. Menaquinones, Bacteria, and the Food Supply: The Relevance of Dairy and Fermented Food Products to Vitamin K Requirements123. Advances in Nutrition [Internet]. 2013 Jul 8;4(4):463–73. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3941825/
  3. Keyvan E, Adesemoye E, Champomier-Vergès MC, Chanséaume-Bussiere E, Mardon J, Nikolovska Nedelkoska D, et al. Vitamins formed by microorganisms in fermented foods: effects on human vitamin status—a systematic narrative review. Frontiers in Nutrition. 2025 Oct 7;12.
  4. Du F, Yan M, Duan L, Xie G, Yao X, Hu W, et al. The study of bioavailability and endogenous circadian rhythm of menaquinone-7, a form of vitamin Kin healthy subjects. British Journal of Nutrition [Internet]. 2023 May 3;130(11):1885–97. Available from: https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/study-of-bioavailability-and-endogenous-circadian-rhythm-of-menaquinone7-a-form-of-vitamin-k2-in-healthy-subjects/8D24A57D07CCF45FDB6450E8D984649F 2,
  5. Yan Q, Zhang T, O’Connor C, Barlow JW, Walsh J, Scalabrino G, et al. The biological responses of vitamin K2: A comprehensive review. Food Science and Nutrition. 2023 Jan 6;11(4):1634–56.
  6. Sato T, Schurgers LJ, Uenishi K. Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women. Nutrition Journal. 2012 Nov 12;11(1).
  7. Bonaldo F, Leroy F. Review: Bacterially produced vitamin K2 and its potential to generate health benefits in humans. Trends in Food Science & Technology [Internet]. 2024 May 1;147:104461. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0924224424001377?via%3Dihub
  8. Mandatori D, Pelusi L, Schiavone V, Pipino C, Di Pietro N, Pandolfi A. The Dual Role of Vitamin K2 in “Bone-Vascular Crosstalk”: Opposite Effects on Bone Loss and Vascular Calcification. Nutrients. 2021 Apr 7;13(4):1222.
  9. Wasilewski GB, Vervloet MG, Schurgers LJ. The Bone—Vasculature Axis: Calcium Supplementation and the Role of Vitamin K. Frontiers in Cardiovascular Medicine [Internet]. 2019 Feb 5;6. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370658/
  10. Schurgers LJ, Dissel PEP, Spronk HMH, Soute BAM, Dhore CR, Cleutjens JPM, et al. Role of vitamin K and vitamin K-dependent proteins in vascular calcification. Zeitschrift f�r Kardiologie. 2001 Apr 1;90(0):III57–63.
  11. Wen L, Chen J, Duan L, Li S. Vitamin K‑dependent proteins involved in bone and cardiovascular health (Review). Molecular Medicine Reports [Internet]. 2018 Apr 27; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059683/
  12. Mrosewski I, Mantel V, Urbank M, Schulze-Tanzil G, Werner C, Gögele C, et al. Menaquinone-7 and its therapeutic potential in type 2 diabetes mellitus based on a Zucker diabetic fatty rat model. Heliyon [Internet]. 2024 Dec 3;10(23):e40826. Available from: https://www.sciencedirect.com/science/article/pii/S2405844024168570
  13. 1stra JW, Draaisma F, Zwakenberg SR, Lessmann N, Wolterink JM, van der Schouw YT, et al. Six months vitamin K treatment does not affect systemic arterial calcification or bone mineral density in diabetes mellitus 2. European Journal of Nutrition. 2020 Oct 17;60(3):1691–9.
  14. Hasific S, Oevrehus KA, Lindholt JS, Mejldal A, Dey D, Dahl JS, et al. Effects of Vitamin K2 and D Supplementation on Coronary Artery Disease in Men: A RCT. JACC: Advances [Internet]. 2023 Nov 1;2(9):100643. Available from: https://www.sciencedirect.com/science/article/pii/S2772963X23006208#:~:text=Conclusions
  15. Kyla Shea, Berkner KL, Ferland G, Fu X, Holden RM, Booth SL. Perspective: Evidence before Enthusiasm—A Critical Review of the Potential Cardiovascular Benefits of Vitamin K. 2021 Jun 1;12(3):632–46.
  16. Akbari S, Rasouli-Ghahroudi AA. Vitamin K and Bone Metabolism: A Review of the Latest Evidence in Preclinical Studies. BioMed Research International [Internet]. 2018 Jun 27;2018:1–8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6040265/
  17. Katarzyna Maresz. Growing Evidence of a Proven Mechanism Shows Vitamin K2 Can Impact Health Conditions Beyond Bone and Cardiovascular. Integrative Medicine: A Clinician’s Journal [Internet]. 2021 Aug;20(4):34. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC8483258/
  18. Bøe CA, Holo H. Engineering Lactococcus lactis for Increased Vitamin K2 Production. Frontiers in Bioengineering and Biotechnology. 2020 Mar 18;8.
  19. Fu X, Harshman SG, Shen X, Haytowitz DB, Karl JP, Wolfe BE, et al. Multiple Vitamin K Forms Exist in Dairy Foods. Current Developments in Nutrition [Internet]. 2017 Jun 1;1(6). Available from: https://academic.oup.com/cdn/article/1/6/e000638/4558638
  20. Vermeer C, Raes J, van ’t Hoofd C, Knapen M, Xanthoulea S. Menaquinone Content of Cheese. Nutrients. 2018 Apr 4;10(4):446.
  21. Field RE;Romanus RJ. An improved gastrostomy technique. IMJ Illinois medical journal [Internet]. 2026 [cited 2026 Feb 11];148(6). Available from: https://pubmed.ncbi.nlm.nih.gov/316
  22. Jensen MB, Daugintis A, Jakobsen J. Content and Bioaccessibility of Vitamin K (Phylloquinone and Menaquinones) in Cheese. Foods. 2021 Nov 29;10(12):2938.
  23. Altuncu V, Kaymaz A, Ertekin Filiz B, Çubuk Demiralay E, Kök Taş T. Evaluation of MENAQUINONE‐7 and fat‐soluble vitamin production by starter cultures during fermentation in dairy products using RPLC method. Food Science & Nutrition. 2024 Oct 26;12(11):9822–33.
  24. Erdoğan AK, Ertekin Filiz B. Menaquinone content and antioxidant properties of fermented cabbage products: Effect of different fermentation techniques and microbial cultures. Journal of Functional Foods [Internet]. 2023 Mar 1;102:105467. Available from: https://www.sciencedirect.com/science/article/pii/S1756464623000671
  25. Australia N. Application for Vitamin K2 (Menaquinone-7, MK-7) as a Substance Used for a Nutritive Purpose in Food for Special Medical Purposes [Internet]. 2024 [cited 2026 Feb 11]. Available from: https://consultations.foodstandards.gov.au/fsanz/a1300-vitamin-k2-as-menaquinone-7-as-a-permitted-f/user_uploads/a1300-application_redacted.pdf
  26. Ren L, Peng C, Hu X, Han Y, Huang H. Microbial production of vitamin K2: current status and future prospects. Biotechnology Advances. 2020 Mar;39:107453.
  27. Halder M, Petsophonsakul P, Akbulut A, Pavlic A, Bohan F, Anderson E, et al. Vitamin K: Double Bonds beyond Coagulation Insights into Differences between Vitamin K1 and K2 in Health and Disease. International Journal of Molecular Sciences. 2019 Feb 19;20(4):896.
  28. Singh R, Puri A, Panda BP. Development of menaquinone-7 enriched nutraceutical: inside into medium engineering and process modeling. Journal of Food Science and Technology. 2014 Oct 18;52(8):5212–9.
  29. Clinic C. Is Sauerkraut Good for You? [Internet]. Cleveland Clinic. 2025. Available from: https://health.clevelandclinic.org/sauerkraut-benefits
  30. Contributors WE. Top Foods High in Vitamin K2 [Internet]. WebMD. 2022. Available from: https://www.webmd.com/diet/foods-high-in-vitamin-k2
  31. Should You Eat More Vitamin K2-Rich Foods? [Internet]. Cleveland Clinic. Available from: https://health.clevelandclinic.org/vitamin-k2-foods
  32. Na S, Ahmad SS, Karim S, Ibrahim IM, Alkreathy HM, Alsieni M, et al. Effect of Vitamin K on Bone Mineral Density and Fracture Risk in Adults: Systematic Review and Meta-Analysis. Biomedicines. 2022 May 1;10(5):1048.
  33. Gundberg CM, Lian JB, Booth SL. Vitamin K-Dependent Carboxylation of Osteocalcin: Friend or Foe? Advances in Nutrition. 2012 Mar 1;3(2):149–57.
  34. Hariri E, Kassis N, Iskandar JP, Schurgers LJ, Saad A, Abdelfattah O, et al. Vitamin K2—a neglected player in cardiovascular health: a narrative review. Open Heart. 2021 Nov;8(2):e001715.
  35. Ma M, Ma Z, He Y, Sun H, Yang B, Ruan B, et al. Efficacy of vitamin K2 in the prevention and treatment of postmenopausal osteoporosis: A systematic review and meta-analysis of randomized controlled trials. Frontiers in Public Health [Internet]. 2022 Aug 11;10. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403798/
  36. Shiraki M, Shiraki Y, Aoki C, Miura M. Vitamin K2 (Menatetrenone) Effectively Prevents Fractures and Sustains Lumbar Bone Mineral Density in Osteoporosis. Journal of Bone and Mineral Research. 2010 Feb 18;15(3):515–21.
  37. Mansour AG, Hariri E, Daaboul Y, Serge Korjian, Andrew El Alam, Protogerou AD, et al. Vitamin K2 supplementation and arterial stiffness among renal transplant recipients—a single-arm, single-center clinical trial. Journal of The American Society of Hypertension. 2017 Sep 1;11(9):589–97.
  38. Bartstra JW, Draaisma F, Zwakenberg SR, Lessmann N, Wolterink JM, van der Schouw YT, et al. Six months vitamin K treatment does not affect systemic arterial calcification or bone mineral density in diabetes mellitus 2. European Journal of Nutrition. 2020 Oct 17;60(3):1691–9.
  39. Schropp N, Bauer A, Stanislas V, Huang KD, Lesker TR, Bielecka AA, et al. The impact of regular sauerkraut consumption on the human gut microbiota: a crossover intervention trial. Microbiome. 2025 Feb 12;13(1).
  40. Stiemsma LT, Nakamura RE, Nguyen JG, Michels KB. Does Consumption of Fermented Foods Modify the Human Gut Microbiota? The Journal of Nutrition. 2020 Mar 31;150(7).
  41. Petre A. 8 surprising benefits of sauerkraut (plus how to make it) [Internet]. Healthline. 2020. Available from: https://www.healthline.com/nutrition/benefits-of-sauerkraut
  42. Booth SL, Centurelli MA. Vitamin K: A Practical Guide to the Dietary Management of Patients on Warfarin. Nutrition Reviews. 2009 Apr 27;57(9):288–96.
  43. Dietary advice for patients taking warfarin [Internet]. Cambridge University Hospitals. 2025. Available from: https://www.cuh.nhs.uk/patient-information/dietary-advice-for-patients-taking-warfarin/
  44. Lopez-Jimenez F. Warfarin diet: What foods should I avoid? [Internet]. Mayo Clinic. 2018. Available from: https://www.mayoclinic.org/diseases-conditions/thrombophlebitis/expert-answers/warfarin/faq-20058443
  45. com. 2019 [cited 2026 Feb 11]. Available from: https://bmjopen.bmj.com/content/13/5/e071885
  46. Schwalfenberg GK. Vitamins K1 and K2: The Emerging Group of Vitamins Required for Human Health. Journal of Nutrition and Metabolism. 2017;2017:1–6.
  47. Akbulut AC, Pavlic A, Petsophonsakul P, Halder M, Maresz K, Kramann R, et al. Vitamin K2 Needs an RDI Separate from Vitamin K1. Nutrients. 2020 Jun 21;12(6):1852.
  48. Sunita A, Siddharth G, Shalini S, Praneeta S, Aparajita S, Garishma G, et al. Vitamin K2: An emerging essential nutraceutical and its market potential. Journal of Applied Biology and Biotechnology. 2022 Feb 15;
  49. Jiang Q, Lin L, Xie F, Jin W, Zhu W, Wang M, et al. Metagenomic insights into the microbe-mediated B and K2 vitamin biosynthesis in the gastrointestinal microbiome of ruminants. Microbiome. 2022 Jul 21;10(1).
  50. Dai L, Mafra D, Shiels PG, Hackeng TM, Stenvinkel P, Schurgers LJ. Vitamin K and Hallmarks of Ageing: Focus on Diet and Gut Microbiome. Nutrients [Internet]. 2023 Jan 1;15(12):2727. Available from: https://www.mdpi.com/2072-6643/15/12/2727
  51. Liu Y, Charamis N, Boeren S, Blok J, Lewis AG, Smid EJ, et al. Physiological Roles of Short-Chain and Long-Chain Menaquinones (Vitamin K2) in Lactococcus cremoris. Frontiers in Microbiology. 2022 Mar 15;13.
  52. Priyadharshini D, Muthuvel I, Saraswathy S, Kavitha PS, Jegadeeswari V. Precision to plate: AI-driven innovations in fermentation and hyper-personalized diets. Frontiers in Nutrition. 2025 Sep 4;12.
  53. From kimchi to kefir: What to tell patients about fermented foods [Internet]. American Medical Association. 2025. Available from: https://www.ama-assn.org/public-health/prevention-wellness/kimchi-kefir-what-tell-patients-about-fermented-foods

‌

Discover more from A1C Almanac

Subscribe now to keep reading and get access to the full archive.

Continue reading